Metropolis reached a new 52-week high today, boosted by robust growth in Q4FY26 revenues by 23%. The healthcare sector also saw surges in stocks for Thyrocare, Vijaya, and Dr Lal PathLabs. Notably, Thyrocare led in volume while Vijaya reported record revenue. A positive outlook for Dr Lal PathLabs was also highlighted.

Metropolis Healthcare has broken out of a symmetrical triangle pattern, indicating potential growth as it records higher lows on significantly increased trading volume. The breakout has also pushed the price above its moving average, suggesting positive momentum.

Metropolis Healthcare reported a 23% increase in Q4 revenue, primarily due to strong performance by TruHealth and specialized testing. Both B2C and B2B segments showed growth, with B2C up 19% and B2B up 30%. Organic revenue also increased by 14.5%, while EBITDA margins improved as well.